Insulet Corporation logo

Insulet Corporation (PODD)

Market Closed
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
289. 32
-8.08
-2.72%
$
21.19B Market Cap
56.74 P/E Ratio
0% Div Yield
499,529 Volume
2.99 Eps
$ 297.4
Previous Close
Day Range
289.03 296.23
Year Range
173 329.33
Want to track PODD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 26 days

Summary

PODD closed today lower at $289.32, a decrease of 2.72% from yesterday's close, completing a monthly decrease of -10.77% or $34.91. Over the past 12 months, PODD stock gained 11.35%.
PODD is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0.25%. On average, the company has surpassed earnings expectations by 0.17%, based on the last three reports. The next scheduled earnings report is due on Aug 07, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

PODD Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?

Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 2 days ago
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod 5 on Improved Health Outcomes at the American Diabetes Association Conference.

Businesswire | 3 weeks ago
Here's Why You Should Retain PODD Stock in Your Portfolio Now

Here's Why You Should Retain PODD Stock in Your Portfolio Now

Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.

Zacks | 1 month ago

Insulet Corporation Dividends

PODD is not paying dividends to its shareholders.

Insulet Corporation Earnings

7 Aug 2025 (In 3 weeks) Date
0.92
Cons. EPS
-
EPS
7 May 2025 Date
0.77
Cons. EPS
1.02
EPS
20 Feb 2025 Date
1.02
Cons. EPS
1.15
EPS
7 Nov 2024 Date
0.76
Cons. EPS
0.9
EPS
31 Oct 2024 Date
0.76
Cons. EPS
-
EPS
PODD is not paying dividends to its shareholders.
7 Aug 2025 (In 3 weeks) Date
0.92
Cons. EPS
-
EPS
7 May 2025 Date
0.77
Cons. EPS
1.02
EPS
20 Feb 2025 Date
1.02
Cons. EPS
1.15
EPS
7 Nov 2024 Date
0.76
Cons. EPS
0.9
EPS
31 Oct 2024 Date
0.76
Cons. EPS
-
EPS

Insulet Corporation (PODD) FAQ

What is the stock price today?

The current price is $289.32.

On which exchange is it traded?

Insulet Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is PODD.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 21.19B.

What is the earnings per share?

The EPS is 0.92.

When is the next earnings date?

The next earnings report will release on Aug 07, 2025.

Has Insulet Corporation ever had a stock split?

No, there has never been a stock split.

Insulet Corporation Profile

Medical - Devices Industry
Healthcare Sector
Ashley A. McEvoy CEO
NASDAQ (NGS) Exchange
45784P101 Cusip
US Country
3,900 Employees
- Last Dividend
- Last Split
15 May 2007 IPO Date

Overview

Insulet Corporation is a pioneering healthcare company that specializes in the development, manufacturing, and sale of innovative insulin delivery systems intended primarily for individuals with insulin-dependent diabetes. Founded in the year 2000 and with its headquarters located in Acton, Massachusetts, Insulet Corporation aims to improve the quality of life for people living with diabetes through its cutting-edge products. The company markets its solutions across a broad geographic spectrum including the United States, Canada, Europe, the Middle East, Australia, and other international markets, leveraging both direct sales and a network of independent distributors and pharmacy channels.

Products and Services

  • Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

The Omnipod 5 stands out as a flagship offering from Insulet Corporation, showcasing a proprietary Automated Insulin Delivery (AID) algorithm built into the Pod. This system is designed to seamlessly integrate with a third-party continuous glucose monitor (CGM), with the aim of obtaining glucose readings via wireless Bluetooth communication. This integration facilitates a dynamic adjustment of insulin delivery, aiming to maintain glucose levels within the target range, hence offering a sophisticated solution to insulin management.

  • Omnipod DASH

Omnipod DASH elevates the convenience of insulin delivery systems by featuring a Bluetooth-enabled Pod, which is managed through a user-friendly Personal Diabetes Manager (PDM). The PDM, resembling a smartphone in its design, comes equipped with a color touch screen user interface. This system provides users a blend of advanced technology and ease of use, making daily diabetes management more manageable and less intrusive.

  • Omnipod GO

The Omnipod GO system introduces a standalone, wearable insulin delivery solution that administers a fixed rate of continuous rapid-acting insulin over a duration of 72 hours. This system is tailored for those seeking simplicity and effectiveness in their insulin therapy, catering especially to individuals who prefer a straightforward approach to diabetes management without the need for frequent adjustments.

Contact Information

Address: 100 Nagog Park
Phone: 978 600 7000